[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503968":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":45,"responsibleParty":63,"collaborators":66,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":25,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":25,"enrollmentInfo":81,"targetDuration":25,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":25,"overallStatus":48,"whyStopped":25,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"QUIT-AD","EXPERIMENTAL","An six-session adapted cognitive-behavioral intervention for smoking cessation and treatment adherence. Intervention content will include psychoeducation related to cognitive-behavioral therapy, smoking, TB, and HIV; behavioral activation; distress tolerance; and relapse prevention.",[13],"Behavioral: QUIT-AD",{"label":15,"type":16,"description":17,"interventionNames":18},"Enhanced Treatment as Usual (ETAU)","ACTIVE_COMPARATOR","After randomization, participants in the ETAU condition will receive one session of psychoeducation on the HIV- and TB-related health benefits of smoking cessation.",[19],"Other: Enhanced Treatment as Usual",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"BEHAVIORAL","An adapted, six-session cognitive behavioral therapy intervention for smoking cessation and treatment adherence",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Enhanced Treatment as Usual","Standard treatment for HIV\u002FTB with one session of psychoeducation.",[15],[31],{"name":32,"affiliation":33,"role":34},"Amelia Stanton, PhD","Boston University","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Conall O'Cleirigh, PhD","CONTACT","617-643-0385","cocleirigh@mgh.harvard.edu",{"name":42,"role":38,"phone":43,"phoneExt":25,"email":44},"Brianna A Estrada, BS","617-643-2147","bestrada@mgh.harvard.edu",[46],{"facility":47,"status":48,"city":49,"state":25,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"University of Cape Town","RECRUITING","Rondebosch","7700","South Africa","ZA",{"type":54,"coordinates":55},"Point",[56,57],18.47639,-33.96333,{"lat":57,"lon":56},[60,62],{"name":61,"role":38,"phone":25,"phoneExt":25,"email":25},"John Joska, PhD",{"name":61,"role":34,"phone":25,"phoneExt":25,"email":25},{"type":34,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Conall O'Cleirigh","Director, Behavioral Medicine\u002FAssociate Professor",[67,68,69],{"name":33,"class":6},{"name":47,"class":6},{"name":70,"class":71},"National Institute on Drug Abuse (NIDA)","NIH","100503968","south-africa-smoking-cessation-and-engagement-in-hivtb-care-care-100503968",false,"NCT05842161","South Africa Smoking Cessation and Engagement in HIV\u002FTB Care Care","Treatment Development for Smoking Cessation and Engagement in HIV\u002FTB","Inclusion Criteria:\n\n1. Aged 18 or older\n2. Willing and able to provide written informed consent\n3. Living with HIV, confirmed via medical record, and on antiretroviral therapy (ART) AND\u002FOR within 1 month of initiating or reinitiating TB treatment; positive GeneXpert test or sputum culture\n\n(5) Daily smoker operationalized as \\> 5 cigarettes per day, (6) Motivation (\\> 5\u002F10) to quit smoking or \\> 24 hour quit past yr\n\nExclusion Criteria:\n\n1. Habitual use of other tobacco products\n2. Current interfering untreated\u002Funstable mental health condition (e.g., psychosis, bipolar dx)\n3. Current use of non-study pharmacotherapy for smoking cessation,\n4. Cognitive Behavioral Therapy for smoking cessation initiated within the past year,\n5. Diagnosed with extra-pulmonary or drug resistant (MDR or XDR) TB based upon chart review","ALL","18 Years",{"count":82,"type":83},86,"ESTIMATED","INTERVENTIONAL",[86],"NA","The purpose of this study is to integrate elements from existing interventions developed by our team into a single intervention (QUIT-AD), designed to improve smoking cessation and favorable HIV\u002FTB treatment outcomes among individuals with HIV and\u002For TB in Cape Town, South Africa. If feasibility, acceptability, and preliminary efficacy are demonstrated, the intervention will be ready for large-scale effectiveness\u002Fimplementation testing. This program will has the potential to dramatically improve public health by increasing the smoking quit rate and facilitating favorable HIV\u002FTB treatment outcomes among patients with HIV and\u002For TB in resource limited South African settings.",[89,90,91],"HIV Infections","Tuberculosis","Smoking Cessation","2026-03-30",{"date":94,"type":95},"2026-04-06","ACTUAL",{"date":97,"type":95},"2024-03-12",{"date":99,"type":83},"2026-05-31",{"name":5,"class":6},1]